Loading...
Because patients with hepatitis C virus (HCV) infection have a greater prevalence of kidney disease and higher risk for progressive renal disease, HCV eradication is essential in this subpopulation. However, safety concerns limit use of many current HCV regimens to those with mild to moderate kidney disease (glomerular filtration rate >30 mL/minute).
Investigators for this multicenter, open-label, phase III study evaluated the safety and efficacy of glecaprevir (NS3/4A protease inhibitor) plus pibrentasvir (NS5A inhibitor) daily for 12 weeks in patients with HCV genotypes 1 to 6 infection, with or without compensated cirrhosis, and stage 4 or 5 chronic kidney disease, with or without dialysis dependency. Patients were HCV-treatment-naive or …